INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma [Yahoo! Finance]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Yahoo! Finance
The drug, in combination with Bristol Myers ' BMY Revlimid (lenalidomide), is approved in the United States and the EU under the brand names Monjuvi and Minjuvi, respectively, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The eligible patient population included cases arising from low-grade lymphoma, who are ineligible for autologous stem cell transplant. More recently, the FDA approved Incyte's Monjuvi in combination with BMY's Revlimid and Roche's Rituxan (rituximab) in mid-2025 for adult patients with relapsed or refractory follicular lymphoma (FL). Last month, the regulatory body in the EU also approved the label expansion of Minjuvi for patients with relapsed or refractory FL, further expanding its presence across hematologic malignancies. Incyte's pivotal phase III frontMIND study evaluating the efficacy and safety of Monjuvi/Minjuvi and Bristol Myers' Revlimid in combination with R-CHOP (Rituxan, cyclophosphamide, do
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Incyte: Buy For The Turnaround, Stay For The Pipeline [Seeking Alpha]Seeking Alpha
- Incyte's Pipeline Potential Signals Massive Upside For Investors [Seeking Alpha]Seeking Alpha
- Factbox-Pharma sector doubles down on AI amid hopes of slashing costs, timelines [Yahoo! Finance]Yahoo! Finance
- Earnings Preview: What To Expect From Incyte's Report [Yahoo! Finance]Yahoo! Finance
- Why Incyte (INCY) Stock Is Trading Up Today [Yahoo! Finance]Yahoo! Finance
INCY
Earnings
- 10/28/25 - Beat
INCY
Sec Filings
- 1/8/26 - Form 4
- 1/7/26 - Form 4
- 1/7/26 - Form 144
- INCY's page on the SEC website